New drug combo tested for tough childhood leukemia
NCT ID NCT04996160
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested whether adding the targeted drug palbociclib to standard chemotherapy is safe for children with acute lymphoblastic leukemia that has returned or not responded to treatment. Only 2 children took part, and the main goal was to find the highest tolerable dose and understand side effects. The study is now complete, but results are not yet widely available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Palbociclib (a targeted cancer drug) combined with chemotherapy drugs (dexamethasone, bortezomib, doxorubicin)
What this could lead to
If this works, it could point toward a new treatment option for children with leukemia that has come back or not responded to standard therapy.
What could go wrong
This was a very early, tiny study (only 2 participants) focused on safety, not effectiveness. The combination may cause significant side effects, and results may not apply to other patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lucile Packard Children's Hospital Stanford
Stanford, California, 94304, United States